Pioneers like Alnylam Pharmaceuticals have led the RNA interference field for years. Now, a crop of young biotechs is ...

Trading on split-adjusted basis will begin at market open on November 29, 2024. This adjustment is expected to help Silexion comply with NASDAQ requirements, enhance its market position, and support ...

GRAND CAYMAN, Cayman Islands, November 22, 2024 - Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for ...

Nearly three decades later, drug makers have developed six approved small interfering RNA (siRNA) therapeutics in the ...

Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report), retaining the price ...

The firm has made significant strides in its RNA editing and RNA interference programs, which are attracting positive attention and positioning the company for differentiation in the treatment of ...

who have also signed separate partnerships to develop new therapies for neurological diseases using RNA interference (RNAi) technology. While there are RNAi products on the marketplace ...

In plants, RNA-dependent RNA polymerase (RDR) plays a key role in RNA interference by suppressing foreign gene expression. By suppressing the expression of the RDR gene family in lettuce ...

The two companies have been working together since 2019 to develop multiple RNA interference (RNAi) candidates for disorders such as non-alcoholic steatohepatitis (NASH), type 2 diabetes ...